Contribute Try STAT+ Today

WASHINGTON — A new report on cannabidiol, or CBD, from the Food and Drug Administration, does little to clarify the agency’s rules for the hemp-derived product.

Companies hoping to put the marijuana-adjacent product in dietary supplements and cosmetic products have long complained that the FDA’s rules are not clear enough to justify their investment in the industry. The latest report, sent to Congress this week, does little to clear that up — it just says the agency is still “evaluating” its policies on the issue.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.